Health Care

Insider trading by Oncology Institute Inc.’s CMO reveals short‑term liquidity moves, not a shift in strategy – learn how 50% revenue growth and a promising FDA‑cleared therapy impact investors and healthcare pros.

Discover what PACS Group insider sales mean for investors – disciplined liquidity moves, not panic, amid strong growth prospects.

Celcuity’s FDA‑approved Revtorpyk shows strong 35% response rates in PIK3CA‑mutant cancers, while insider sales by Baker Bros. reflect strategic liquidity moves, not a bearish signal.

GALECTIN THERAPEUTICS insider trades reveal CMO confidence in its fibrotic disease pipeline, balancing gains and risk with Rule 10b5‑1 buys, sales, and option exercise.

Opaleye’s July share sale shows strategic rebalancing, not a warning, for Eton Pharmaceuticals – whose eye and skin biologics move from Phase II to fast‑track Phase III, backed by strong safety data and global IND approvals.

Dexcom insider selling: Michael Brown’s July 15th sale shows disciplined portfolio rebalancing amid rising payor negotiations, telehealth growth, and AI‑driven CGM innovation.

BVF Partners’ $39 cash exit from XOMA Royalty Corp shows a profit‑taking, value‑play trend, highlighting the role of CVRs, shifting ownership, and potential upside in biotech royalty assets.

Insightful guide to Clover Health’s sell‑to‑cover insider sales—why they’re routine, not a red flag, and how to track future price moves.

Dr. John Markels’ 23,029‑share option exercise at VAXCYTE signals board confidence but raises dilution concerns—watch the 2027 vesting and market response.

Alignment Healthcare insider trading: President’s July 15 10b‑5‑1 buy‑sell sequence shows compliant liquidity management, no market‑moving impact.